MAIN CONFERENCE 12/17 - PT (Pacific Time, GMT-08:00)
MAIN CONFERENCE 12/17 - PT (Pacific Time, GMT-08:00)
6:30am - 7:15am45 mins
Sunrise Yoga: Wellness Event
7:15am - 7:30am15 mins
Registration
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #1
Unlocking Therapeutic Discovery: ATX-Gx™ Humanized Mouse Platform
- John "Lippy" Lippincott, PhD - Senior Vice President of Therapeutic Discovery Strategies, Alloy Discovery Services
7:30am - 8:00am30 mins
Scientific Breakfast Briefing #2
A Base-Stable Protein G Solid Phase for the Purification of Human Monoclonal Antibodies
- Alistair Hurst - Director of Business Development (Global), emp Biotech GmbH
8:10am - 8:15am5 mins
Track 1: Novel Bispecific and Multi-specific Antibodies
Co-Chairs’ Remarks - Novel Bispecific and Multi-specific Antibodies
- Janine Schuurman, Ph.D. - Biotech Consultant, Lust for Life Science
- James Ernst, Ph.D. - Vice President, Head of Protein Sciences and Technology Department, Xencor
8:10am - 8:15am5 mins
Track 2: Antibodies for Metabolic Disease and Neurodegeneration
Co-Chairs' Remarks - Antibodies for Metabolic Disease and Neurodegeneration
- James Larrick, MD, PhD - Managing Director and Chief Medical Officer , Panorama Research Institute
- Katrin Svensson, Ph.D. - Assistant Professor, Department of Pathology, Stanford School of Medicine
8:15am - 8:45am30 mins
Track 1: Novel Bispecific and Multi-specific Antibodies
DuoBody-EpCAMx4-1BB Facilitates Conditional T-cell Co-stimulation and Augments Antitumor Activity in Preclinical Studies
- Kristel Kemper, Ph.D. - Director, Translational Research, Genmab
8:15am - 8:45am30 mins
Track 2: Antibodies for Metabolic Disease and Neurodegeneration
Targeting Na+/K+ ATPase to Treat Neurodegenerative Diseases
- Jinsong Bian, Ph.D. - Professor and Head Department of Pharmacology, Southern University of Science and Technology
8:45am - 9:15am30 mins
Track 1: Novel Bispecific and Multi-specific Antibodies
BiCE™ - An Antibody Platform to Potentiate Complement Activation for the Treatment of Cancer and Autoimmune Diseases
- Mikael Winkler, Ph.D. - CTO & Co-founder, Commit Biologics
8:45am - 9:15am30 mins
Track 2: Antibodies for Metabolic Disease and Neurodegeneration
GDF-15 Neutralization with Ponsegromab: A Potential Treatment for Cachexia
- Danna Breen, Ph.D. - Research Fellow, Pfizer
9:15am - 9:45am30 mins
Track 1: Novel Bispecific and Multi-specific Antibodies
Extracellular protein degradation by biparatopic sweeping antibody
- Eriko Matsuda - Head of Lead Identification, Discovery Biologics, Chugai Pharmaceutical Co. Ltd.
9:15am - 9:45am30 mins
Track 2: Antibodies for Metabolic Disease and Neurodegeneration
Identification of Novel Metabolic Targets
- Katrin Svensson, Ph.D. - Assistant Professor, Department of Pathology, Stanford School of Medicine
9:45am - 10:30am45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
- Alon Wellner, PhD - Vice President Biology and Co-Founder, Aureka Biotechnologies
10:30am - 11:00am30 mins
Track 1: Novel Bispecific and Multi-specific Antibodies
Discovery and Development of an Antibody Agonist Leveraging Experimental and Computational Methods
- Alexey Lugovskoy, Ph.D. - President and CEO, Diagonal Therapeutics
10:30am - 11:00am30 mins
Track 2: Antibodies for Metabolic Disease and Neurodegeneration
AAV-based anti-RAN antibody therapy for C9orf72 ALS/FTD
- Laura Ranum, Ph.D. - Director, Center for NeuroGenetics, University of Florida
11:00am - 11:30am30 mins
Track 1: Novel Bispecific and Multi-specific Antibodies
Machine Learning-guided Design of Next-generation Logic Gated and Avidity-driven T Cell Engagers for Patients with Solid Malignancies
- Ryan Henrici, M.D., Ph.D. - Vice President, Discovery Medicine, BigHat Biosciences
11:00am - 11:30am30 mins
Track 2: Antibodies for Metabolic Disease and Neurodegeneration
CNS Delivery of Biologics Using Bispecific Antibodies Targeting CD98hc and Transferrin Receptor
- Yunxuan Xie, PhD Candidate - Graduate Research Assistant, University of Michigan
11:30am - 12:00pm30 mins
Track 1: Novel Bispecific and Multi-specific Antibodies
Bispecific Antibodies for Oncology and Autoimmune Diseases
- John Desjarlais, PhD - Chief Scientific Officer, Xencor, Inc.
11:30am - 12:00pm30 mins
Track 2: Antibodies for Metabolic Disease and Neurodegeneration
Harnessing Alector Brain Carrier (ABC) to Deliver Novel Neuroimmunology Therapies to the CNS
- Eric Brown, Ph.D. - Associate Director, Protein Engineering, Alector
12:05pm - 12:35pm30 mins
Scientific Briefing 1
Cutting Through the Hype: Real-World Applications of AI in Antibody Discovery and Engineering
- Barry Duplantis, Ph.D. - Director of Global Business Development, Ailux Biologics by XtalPi
12:05pm - 12:35pm30 mins
Scientific Briefing 2
An Integrated approach for Characterizing and Managing Immunogenicity Risk
- Emilee Knowlton, Ph.D. - Immunology Sales Specialist , ProImmune, Inc.
12:05pm - 12:35pm30 mins
Scientific Briefing 3
Streamlined Antibody and Therapeutic Development Using The Pfenex Expression Technology® Platform
- Diane Retallack, PhD - President & COO, Primrose Bio
12:05pm - 12:35pm30 mins
Scientific Briefing 4
Atlas™ Mice Provide a New and Differentiated Toolset for Rapid Generation of Developable Human Therapeutic Antibodies
- Dan Rohrer, PhD - Chief Technology Officer, AbTherx
12:05pm - 12:35pm30 mins
Scientific Briefing 5
Simplified and Humanized: Empowering Humanized Antibody Discovery with AbDropTM Solution
- Lei Shi, PhD - Senior Vice President, Biointron Biological
12:35pm - 1:45pm70 mins
Networking Luncheon, Exhibit and Poster Viewing
- Maria Germana Sanna, PhD - Field Application Scientist-West Coast, Gyros Protein Technologies
- Ajay Sapre, PhD - Senior Scientist, Research & Development, Parse Biosciences
- Ammar Arsiwala, PhD - Technical Lead, Antibody Developability, Ginkgo Bioworks
- Mary Dwyer, PhD - Scientist, KACTUS
1:45pm - 2:15pm30 mins
Scientific Briefing 1
Integrating Synthetic Biology and Computer-aided Design to Advance Biologics Production in CHO Cells
- Imroz Ghangas - Senior Director Business Development, Asimov
1:45pm - 2:15pm30 mins
Scientific Briefing 2
Breaking Barriers in Antibody Discovery with Innovative Cell Isolation
- Allison Schulkins - Chief Operating Officer, Single Cell Technology
1:45pm - 2:15pm30 mins
Scientific Briefing 3
Asymmetric Bispecific Antibody Purification Platforms
- Mats Ander - Project Manager, Cytiva
1:45pm - 2:15pm30 mins
Scientific Briefing 4
Faster Antibody Discovery with Automated Bioinformatics Pipelines - Flexible in silico Analysis for Antibody Discovery and Development
- Jannick Bendtsen, PhD - CEO, PipeBio
1:45pm - 2:15pm30 mins
Scientific Briefing 5
Innovating Bi-specific T Cell Engagers with Nona Biosciences' HBICE® Platform
- Joe Zhao - Vice President, Nona Biosciences
2:25pm - 2:30pm5 mins
Track 1: Innovative Concepts in Cell Engagers
Co-Chairs’ Remarks - Innovative Concepts in Cell Engagers
- Shelley Force Aldred, Ph.D. - CEO, Rondo Therapeutics
- Eric Smith - Executive Director - Bispecifics, Regeneron Pharmaceuticals
2:25pm - 2:30pm5 mins
Track 2: Antibody-Based Approaches to Treat Autoimmunity
Chairman’s Remarks - Antibody-Based Approaches to Treat Autoimmunity
- John Desjarlais, PhD - Chief Scientific Officer, Xencor, Inc.
2:30pm - 3:00pm30 mins
Track 1: Innovative Concepts in Cell Engagers
Combination Strategies to Enhance Anti-tumor T cell Response
- Eric Smith - Executive Director - Bispecifics, Regeneron Pharmaceuticals
2:30pm - 3:00pm30 mins
Track 2: Antibody-Based Approaches to Treat Autoimmunity
Leveraging Formation of Post-translationally Modified Neoepitopes to Targeting Therapeutic Specifically to Diseased Tissue
- Ahuva Nissim, Ph.D. - Prof in Antibody and Therapeutic Engineering, Queen Mary University
3:00pm - 3:30pm30 mins
Track 1: Innovative Concepts in Cell Engagers
Co-stimulatory Bispecific Antibody Strategies for Treating Solid Tumors
- Katherine Harris, PhD - Chief Development Officer, Rondo Therapeutics
3:00pm - 3:30pm30 mins
Track 2: Antibody-Based Approaches to Treat Autoimmunity
Briquilimab, An anti-c-Kit Monoclonal Antibody, As A Potential Therapeutic for Mast Cell-related Disorders
- Wendy Pang, M.D., Ph.D. - SVP Research and Translational Medicine, Jasper Therapeutics
3:30pm - 4:00pm30 mins
Track 1: Innovative Concepts in Cell Engagers
EVOLVE: Advanced T Cell Engagers with Integrated CD2 Costimulation
- Martin Preyer, Ph.D. - Executive Director, Biotherapeutics, Evolveimmune Therapeutics
3:30pm - 4:00pm30 mins
Track 2: Antibody-Based Approaches to Treat Autoimmunity
Obexelimab: A Differentiated B cell Targeted Antibody for Treatment of Autoimmune Diseases
- Xiao Feng, Ph.D. - Vice President, Head of Research, Zenas BioPharma
4:00pm - 4:45pm45 mins
Networking Refreshment Break, Exhibit and Poster Viewing
- Sebastian Giehring, PhD - CEO, PAIA Biotech
4:45pm - 5:15pm30 mins
Track 1: Innovative Concepts in Cell Engagers
Co-stimulatory IgM T-cell Engagers with Enhanced and Durable Cytotoxicity against Solid Tumors
- Angus Sinclair, PhD - Executive Vice President, Research, IGM Biosciences
4:45pm - 5:15pm30 mins
Track 2: Antibody-Based Approaches to Treat Autoimmunity
Forced Proximity and Cotargeting for Autoimmune Diseases
- Pam Holland, Ph.D. - Senior Vice President, Biology, InduPro
5:15pm - 5:45pm30 mins
Track 1: Innovative Concepts in Cell Engagers
Engineered Monoclonal IgA for the Treatment of Cancer
- Mitchell Evers, Ph.D. - Assistant Professor, UMC Utrecht
5:15pm - 5:45pm30 mins
Track 2: Antibody-Based Approaches to Treat Autoimmunity
DNTH103, a Highly Potent, Potentially Safer and More Convenient Novel Investigational Therapy in Development for Rare Neuromuscular Autoimmune Diseases
- Jeffrey Stavenhagen, Ph.D. - Chief Scientific Officer, Dianthus Therapeutics
5:45pm - 6:15pm30 mins
Track 1: Innovative Concepts in Cell Engagers
A New Generation of Tumor-Microenvironment Activated ThErapeutic (T-MATE) to Treat Solid Tumors
- Aude Segaliny, PhD - Senior Director, Head of Research & Early Development, Amberstone Biosciences
5:45pm - 6:15pm30 mins
Track 2: Antibody-Based Approaches to Treat Autoimmunity
Engineered Regulatory T cell Therapy for Autoimmune and Inflammatory Disorders
- Joseph Arron, M.D., Ph.D. - Chief Scientific Officer, Sonoma Biotherapeutics
6:15pm - 7:15pm60 mins
Networking Reception, Exhibit and Poster Viewing
* 活动内容有可能不事先告知作更动及调整。